

Investor Presentation Full Year FY 2013

Rory Macleod, Managing Director

September 2013



Disclaimer

This presentation dated 2nd September 2013 provides additional comment on the market release of 29th August 2013 and the Full Year Report. As such, it should be read in conjunction with, and subject to, the explanations and views in those documents.

This presentation is provided for information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and consider talking to a financial adviser or consultant before making any investment decision.

Certain statements in this presentation constitute forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company and which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements.

While all reasonable care has been taken in relation to the preparation of this presentation, none of the Company, its subsidiaries, or their respective directors, officers, employees, contractors or agents accepts responsibility for any loss or damage resulting from the use of or reliance on the presentation by any person.

Past performance is not indicative of future performance and no guarantee of future returns is implied or given. Some of the information in this presentation is based on unaudited financial data which may be subject to change. All values are expressed in Australian currency unless otherwise stated.

All intellectual property, proprietary and other rights and interests in this presentation are owned by the Company.



Safe, Nutritious, Longer Life

We believe that people's needs have moved towards safer, nutrient rich, longer life convenient foods.

All our products have a purpose of bringing value to consumers lives through best nutrition and innovative convenience.





Freedom Foods
Better food for
everyone

Specialty
Seafood Brands

Pactum Australia Innovative UHT Packaging Solutions A2 Specialised Milk Products





nount"

















Freedom Foods


- Strong momentum from FY 2012
- Core Cereals sales of 1 million cases (50% volume / 41% sales)
 - New product innovation
 - Increased distribution points, shelf weights, user frequency
 - Increasing international sales (based on allergen free / non GMO claims)
 - Cereal growth driving increased Leeton efficiencies, including labour, supply chain and distribution
- Dairy Alternative beverage growth of 14% volume / 24% sales
 - Increased market share of Australia Own Organic and Blue Diamond Almond Milk
- Breakfast snack and nut free snacks recorded growth of 127%, albeit from a small base
- Significantly increased Business EBDITA contribution




Freedom Foods

Strong growth in Health Cereals Category

Freedom Share of Health Cereals
































Key Highlights

Non Dairy Beverages
 Significant growth in Almond Category, Soy & Rice Category Declining







Key Highlights


Freedom share of Non Dairy

Freedom Non Dairy Share



Freedom Almond Category Share











Development Activity

Business leveraging core manufacturing capabilities



Leeton Manufacture Aug 13

USA Ranging Development







Launching Sept 13



NPD July 13



Freedom Foods – Next 12 Months

- Increasing Sales
 - New product development (Cereals, Dairy Alternative Beverages)
 - Increasing distribution points and stock weights
 - New channel development (Food Service, Industrial)
 - Driving awareness of brand and products across a broader consumer base with brand and product innovation relevant to health conscious consumers
 - Building North America retail presence based unique point of differentiation (free of allergens and Non GMO)
- Upgrade to Cereal packaging capability at Leeton, providing increased capacity, product capability and lower cost
- Upgrade to Extrusion capability (growth domestic and USA)
- Bar capabilities expansion







Specialty Seafood

- Brunswick Sardines and Paramount Salmon
- Brunswick sardines maintained its No 1 brand leadership position in Australia and New Zealand.
- In Salmon, Paramount increased its share in the Pink Salmon segment, although the brand suffered SKU ranging reductions in the 2nd half.
- The Speciality Seafood business performed below the previous corresponding period, reflecting lower sales in New Zealand and increased cost of Salmon.
- The business continued to utilise the procurement power of Bumble Bee Foods of North America, with Bumble Bee securing inventory requirements through priority access to Salmon and Sardine catch volumes.



Specialty Seafood Range













Specialty Seafood - Next 12 Months

- Maintain competitive range in Core Sardine and Salmon Products
- Build on Brunswick Specialty Position
 - Increase value added and snack offerings
 - Leveraging Canadian Origin, Omega 3 function and versatility
 - New branding focus aligned with above
- Leverage Procurement alliance with Bumble Bee Foods
 - Pricing and Supply advantages to our business
- Consistent performance over many years, assisting sales, marketing infrastructure to build group business units







- Innovative Contract Solutions in UHT (Long Life) Food & Beverage Products
- Non-dairy production volumes increased during the year to support the growth of the Freedom Foods Australia's Own and Blue Diamond brands, in particular focussed on the fast growing almond beverage category.
- The business continued to see benefit at its Sydney facility of increasing its mix of value added UHT products to a range of private label and proprietary customers, while migrating out of standard dairy milk production.
- Expansion of Packaging Capabilities
 - Portion Pack (250ml Capabilities) commissioned from January 13
 - Significantly increased depth and breadth of customers and sales
 - Well advanced on construction of UHT facility for export (China, SE Asia) for UHT dairy based in Shepparton, Victoria
- Strong Business EBDITA contribution



Core Range Formats UHT Beverages, Foods

Australasia Focus



- UHT facility at Shepparton well progressed
- The initial capabilities of the plant will be 200ml portion pack and 1 Litre UHT configuration.
- Initial capacity will be up to 100m litres, with capability to significantly increase this capacity in the longer term.
- Trial production to commence in December 2013.
- The business is well advanced in securing volumes to meet its base business plan for 2014, with a phased development over 3 years.







- New formats for Premium and On the Go Food & Beverage Positioning
- On the go convenience and premium differentiation
- Both capabilities will be for domestic customers and dairy based export customers.
- From FY 15 and phased development over 3 years.





Product Examples



Pactum Australia - Next 12 Months

- Innovative Contract Solutions in UHT (Long Life) Food & Beverage Products
- Expansion of packaging capabilities in Pactum will result in an increase in sales and profitability in the FY 14
- Additional growth opportunities available through meeting the increasing demands of its private label and proprietary customer base.
- Investment in Pactum Dairy Group provides a potential medium term opportunity to increase exposure to the growing demand for high quality and safe dairy products from South East Asia, including China.
- Key long term value added supply relationships into China and SE Asia:
 - A2 Dairy; and
 - China based Shenzhen JLL Group (JLL)





A2 Corporation – 18.04% Strategic Investment


- a2[™] branded milk is the fastest growing milk brand in the Australian market with 7.4% of grocery channel market share by value. Sales growth in Australia increased 48%.
- a2[™] brand milk in the UK market established in five retailer groups and 1000 retail outlets
- a2[™] Platinum[™] infant formula into China with first shipment invoiced in June 13, with sales planned from November 2013. Infant formula is planned for launch in Australia from September 2013.
- In December 2012, FNP sold 40m shares in A2C at NZ\$0.50, for a total net consideration of \$15.4 million, recording a pre tax profit of \$11.8m.
- FNP's 18.04% investment valued at around A\$72 million, materially above the book value of A\$9.9 million.



Current geographical and product overview



Geographic overview



Current product offering



















Source: A2 Corporation Web Site



Financial Highlights – Full Year FY 2013

- Operating EBDITA of \$11.6 million, an increase of 113%
- Net Operating Profit was \$6.4 million, an increase of 92%, including an increase in operating income tax expense to \$1.8 million, against \$185k for the prior year period.
- The Reported Net Profit of \$13.7 million included non-operating after tax profit of \$8 million from the sale of 40 million shares in A2 Corporation, employee share option expense of \$246k (after tax), bad debts provision of \$205k (after tax) and resolution of a long term employee claim of \$140k (after tax). The Company is utilising future income tax benefits to reduce cash tax payable on the sale of the A2C shareholding.
- Equity Associates contributions of \$0.8 million reflected share of estimated year end profits from A2 Corporation including share of profits from FY 2012 not previously recognised.



Financial Highlights – Full Year FY 2013

- The Company completed a successful capital raising of \$17.4 million (gross proceeds) at \$1.04 per share from a placement and entitlements offer in March 2013.
- Net Debt / Equity at 10% from 82% at June 2012, reflected the sell down of the A2C shareholding and exercise of options by shareholders as well as the \$17.4m capital raising during the period.
- Net assets per share at \$0.63 and net tangible assets of \$0.47 per share,
 with A2C investment recorded at a book value of \$9.9 million.
- The Company is to pay a final dividend for the year of \$0.01 per ordinary share (fully franked) in November 2013, equating to a total ordinary share dividend of \$0.02 for the year. A fully franked converting preference share dividend will be paid in November 2013.



Financial Summary – Full Year FY 2013

12 months to 30 June	2013	2012 \$'000	% Change
Gross Sales Revenues (1)	115,516	72,556	+59.2%
Net Sales Revenues (1)	98,718	58,134	+69.8%
EBDITA (Operating) (2)	11,600	5,447	+113.0%
EBITA (Operating) (2)	8,972	4,075	+120.2%
Equity Associates Share of Profit	819	1,214	-32.5%
Pre Tax Profit (Operating)	7,524	3,476	+116.5%
Pre Tax Profit (Reported)	18,524	3,250	+470.0%
Net Profit (Operating)	6,351	3,305	+92.2%
Net Profit (Reported)	13,722	3,012	+355.6%
Total Ordinary Dividend (cps)	\$0.020	\$0.010	+100%
Total CRPS Dividend (cps)	\$0.028	\$0.028	-
EPS (cents per share)(Fully Diluted for CRPS)	11.39	3.03	+275.9%
Net Debt / Equity	10%	82%	-87.8%
Net Assets per Share	\$0.63	\$0.49	+29.6%
Net Tangible Assets per Share	\$0.47	\$0.26	+75.7%



FFG in Summary

- Market Opportunity
 - Large categories Health/dietary-driven segments growing rapidly.
- Platform for Growth Established
 - Cereals, Snacks, facility, products and brand
 - Pactum stable base, growth in customer driven capacity expansion
 - A2 milk, Australian success, growing globally
- High barriers to entry in Freedom 'free from', UHT and A2
- Geographic exposure growing (Asia and North America)
- Stable, growing, earnings and cashflows on sales revenues of +\$100m
- Proven Management Team and Board



Issued Capital and Shareholding Base

- Issued Capital
 - 114.8m Ordinary Shares
 - 17.2m CRPS (9% Yield) (Buyback rights from Dec 13)
 - 1.4m Options over Ordinary Shares (@\$0.40)
 - 10.0m Employee Options
- Significant change in Register in last 9 months
 - Outside of Perich Group, more than 51% of register has traded since July 12

Rank	Name	28 Aug 13	%IC
1	PERICH GROUP	69,225,122	60.30%
2	RBC INVESTOR SERVICES AUSTRALIA NOMINEES PTY LIMITED	6,788,026	5.91%
3	CITICORP NOMINEES PTY LIMITED	6,700,354	5.84%
4	UBS NOMINEES PTY LTD	5,769,363	5.03%
5	NATIONAL NOMINEES LIMITED	4,251,132	3.70%
6	MIRRABOOKA INVESTMENTS LIMITED	1,850,000	1.61%
7	BNP PARIBAS NOMS PTY LTD	1,479,723	1.29%
8	TELUNAPA PTY LTD	1,225,000	1.07%
9	UBS WEALTH MANAGEMENT AUSTRALIA NOMINEES PTY LTD	937,652	0.82%
10	MR STEPHEN FRANCIS HIGGS & MRS ROSEMARY JEAN HIGGS	859,024	0.75%



Appendices

FREEDOM FOODS GROUP LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2013

Notes	Consolidated \$000	
	2013	2012
7(a)	,	767
	,	17,746
		81
	,	13,144
_		644
-	49,134	32,382
	9,909	12,357
	1,146	2,035
	45,162	35,619
	5,214	5,214
_	16,274	16,274
_	77,705	71,499
_	126,839	103,881
	15,847	15,196
4	14,282	19,001
	4,375	816
5	-	8,064
	472	
	1,217	902
_	36,193	43,979
	63	73
4	8,066	12,395
	122	164
_	8,251	12,632
_	44,444	56,611
_	82,395	47,270
	62.978	39,508
		(3,901)
		11,663
-		47,270
-	02,000	,_10
	7(a)	\$00 2013 7(a) 14,106 19,076 148 14,886 918 49,134 9,909 1,146 45,162 5,214 77,705 126,839 15,847 4 14,282 4,375 5 472 1,217 36,193 4 8,066 122 8,251 44,444

Notes to the financial statements are included.

FREEDOM FOODS GROUP LIMITED

Payments to suppliers and employees (81,605) (50,495) Cash generated from operations 5,875 5,431 Interest and other costs of finance paid (1,979) (1,808) Income tax (paid) / refund (353) (1115) 182 Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities 2 18 Proceeds from disposal of property, plant and equipment 5,880 (5,144) Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - Net cash inflow on acquisition of subsidiary 1 6 Investment in PDG (4,313) - Advance to Joint Venture 2 (4,313) - Net cash used in investing activities 24,109 211 Payment of shares 24,109 211 Payment of share issue costs (72) (6 C		Notes	Consoli	
Cash flows from operating activities 87,480 55,926 Receipts from customers 81,605) 55,926 Payments to suppliers and employees (81,605) 50,485 Cash generated from operations 5,875 5,431 Income tax (paid) / refund (353) (119) Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities 5,870 18 18 Proceeds from disposal of property, plant and equipment (5,880) (5,144 18 Payment for property, plant and equipment (5,880) (5,144 18				
Receipts from customers 87,480 55,926 Payments to suppliers and employees (81,605) (50,495) Cash generated from operations 5,875 5,431 Interest and other costs of finance paid (1,979) (1,808) Income tax (paid) / refund 3533 (119 Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities Proceeds from disposal of property, plant and equipment - 18 Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from acquisition of subsidiary 15,277 - Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture 2 1,438 Net cash used in investing activities 24,109 211 Proceeds from financing activities 24,109 211 Proceeds from borrowings 4,20			2013	2012
Payments to suppliers and employees (81,605) (50,495) Cash generated from operations 5,875 5,431 Interest and other costs of finance paid (1,979) (1,808) Income tax (paid) / refund (353) (1115) 182 Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities 2 18 Proceeds from disposal of property, plant and equipment 5,880 (5,144) Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - Net cash inflow on acquisition of subsidiary 1 6 Investment in PDG (4,313) - Advance to Joint Venture 2 (4,313) - Net cash used in investing activities 24,109 211 Payment of shares 24,109 211 Payment of share issue costs (72) (6 C	Cash flows from operating activities			
Cash generated from operations 5,875 5,431 Interest and other costs of finance paid (1,979) (1,808) Income tax (paid) / refund (353) (119) Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities Proceeds from disposal of property, plant and equipment - 18 Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 168 Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6 Dividends paid (2,327) (1,020)	Receipts from customers		87,480	55,926
Interest and other costs of finance paid (1,979) (1,808) Income tax (paid) / refund (353) (119) Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,636 3,	Payments to suppliers and employees		(81,605)	(50,495)
Receipt of government grants 115 128 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities 7(b) 3,658 3,686 Proceeds from disposal of property, plant and equipment 5,880 (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares (20) (2,064) Investment in PDG (4,313) Investment in PDG (4,313) Advance to Joint Venture (1,438) Net cash used in investing activities (2,327) Cash flows from financing activities (2,327) Proceeds from issue of shares (2,327) Dividends paid (2,327) Proceeds from borrowings (2,327) Repayment of borrowings (1,2257) Repayment of related party loan (8,387) Proceeds from related party loan (8,387) Proceeds from related party loan (8,387) Proceeds from related party loan (8,387) Proceeds in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182 Cash and cash equivalents at beginning of financial year (13,339) Cash and cash equivalents at beginning of financial year (13,339) Cash and cash equivalents at beginning of financial year (13,339) Cash and cash equivalents at beginning of financial year (13,339) Cash and cash equivalents (13,339) Cash and cash equivalents	Cash generated from operations	_	5,875	5,431
Receipt of government grants 115 182 Net cash provided by operating activities 7(b) 3,658 3,686 Cash flows from investing activities Proceeds from disposal of property, plant and equipment 5,880 (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture 5,064 (8,460) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,337) (1,020) Proceeds from issue of shares 24,109 211 Repayment of borrowings (2,257) (3,401) Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - <	Interest and other costs of finance paid		(1,979)	(1,808)
Cash flows from investing activities 7(b) 3,658 3,686 Proceeds from disposal of property, plant and equipment - 18 Payment for property, plant and equipment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan (8,387) - Proceeds from related party loan (8,387) - Proceeds from related party loan (Income tax (paid) / refund		(353)	(119)
Cash flows from investing activities Proceeds from disposal of property, plant and equipment - 18 Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - 168 Net cash inflow on acquisition of subsidiary - 168 - 168 Investment in PDG (4,313) - (1,438) Advance to Joint Venture - (1,438) - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (72,2) (6 Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - 2,064 Net cash provided by financing activities 4,617 5,359 Net cash and cash equivalents 767 585	Receipt of government grants	_		182
Proceeds from disposal of property, plant and equipment - 18 Payment for property, plant and equipment (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 - Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6 Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings 4,201 7,511 Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 767 5,355 Ocash and cash equivalents at beginning of financial year 13,339	Net cash provided by operating activities	7(b)	3,658	3,686
Payment for property, plant and equipment in Equity Interest (5,880) (5,144) Investment in Equity Interest (20) (2,064) Proceeds from sale of Equity shares 15,277 168 Net cash inflow on acquisition of subsidiary (4,313) - Investment in PDG (4,313) - Advance to Joint Venture - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6 Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339	Cash flows from investing activities			
Investment in Equity Interest (20) (2,064)	Proceeds from disposal of property, plant and equipment		_	18
Proceeds from sale of Equity shares 15,277 Net cash inflow on acquisition of subsidiary - 168 Investment in PDG (4,313) - Advance to Joint Venture 5,064 (8,460) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Payment for property, plant and equipment		(5,880)	(5,144)
Net cash inflow on acquisition of subsidiary Investment in PDG 4 (4,313) 6 (4,313) 7 (1,436) Advance to Joint Venture 5,064 (8,460) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan (8,387) - Proceeds from related party loan 4,617 5,350 Net cash provided by financing activities 767 585 Osh and cash equivalents at beginning of financial year 13,339 182	Investment in Equity Interest		(20)	(2,064)
Investment in PDG	Proceeds from sale of Equity shares		15,277	-
Advance to Joint Venture - (1,438) Net cash used in investing activities 5,064 (8,460) Cash flows from financing activities - 24,109 211 Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6 Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - 2,064 Net cash provided by financing activities 4,617 5,355 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Net cash inflow on acquisition of subsidiary		-	168
Cash flows from financing activities 5,064 (8,460) Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Investment in PDG		(4,313)	-
Cash flows from financing activities Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings (4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Advance to Joint Venture	_	-	(1,438)
Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Net cash used in investing activities	-	5,064	(8,460)
Proceeds from issue of shares 24,109 211 Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Cash flows from financing activities			
Payment of share issue costs (722) (6) Dividends paid (2,327) (1,020) Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182			24.109	211
Proceeds from borrowings 4,201 7,511 Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Payment of share issue costs			(6)
Repayment of borrowings (12,257) (3,401) Repayment of related party loan (8,387) - Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,358 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Dividends paid		(2,327)	(1,020)
Repayment of related party loan (8,387) - - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Proceeds from borrowings		4,201	7,511
Proceeds from related party loan - 2,064 Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Repayment of borrowings		(12,257)	(3,401)
Net cash provided by financing activities 4,617 5,359 Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Repayment of related party loan		(8,387)	-
Net increase in cash and cash equivalents 767 585 Cash and cash equivalents at beginning of financial year 13,339 182	Proceeds from related party loan		-	2,064
Cash and cash equivalents at beginning of financial year 13,339 182	Net cash provided by financing activities	_	4,617	5,359
	·			585
Cash and cash equivalents at end of financial year 7(a) 14,106 767		_	,	182
	Cash and cash equivalents at end of financial year	7(a)	14,106	767



Appendices

Net tangible assets per security

	30 June 2013	30 June 2012
Net tangible assets (in thousands of AUD)	60,907	25,782
Net assets (in thousands of AUD)	82,395	47,270
Total number of ordinary shares (in thousands)	113,754	77,996
Total number of converting redeemable preference shares (in thousands)	17,219	19,415
Total number of shares (ordinary + CRPS)	130,973	97,411
Net assets per security (in dollars of AUD)	0.63	0.49
Net tangible assets per security (in dollars of AUD)	0.47	0.26

Segmented Reporting (FY 2013)

Net Sales	EBDITA	EBDITA % NSV
40,070	6,124	15.3%
15,788	2,717	17.2%
55,858	8,841	15.8%
42,828	6,427	15.0%
98,686	15,268	15.5%
	-3,668	
98,686	11,600	11.8%
	15,788 55,858 42,828 98,686	40,070 6,124 15,788 2,717 55,858 8,841 42,828 6,427 98,686 15,268 -3,668

Note: Reported Net Sales includes internal Pactum Sales to Freedom Foods, which is deconsolidated under accounting standards





